Korean drug developer buys skincare seller 75x its size for $2.77M
What's the deal? Shaperon, a Korean drug developer, has bought 60% of NeedsTech, a skincare and home-care seller, for US$3.1M in cash. It completed the deal on July 2, 2026. The target books more than US$14.3M in annual revenue — roughly 75 times Shaperon's size.
What did Shaperon buy? The price covered 60,000 shares held by NeedsTech chief executive Jeon Sang-yeon, who keeps the other 40% and stays on as co-CEO. Shaperon also secured a right of first refusal on those remaining shares. The business sells under two brands, Hugrab in home healthcare devices and Bude in skincare, through channels including Olive Young, Electronic Land and Kakao Gift.
The terms: The price implies about US$5.2M for the whole company — roughly 0.36 times 2025 revenue. NeedsTech started in 2020 with US$251.5K in sales and passed US$14.3M in both 2024 and 2025.
Why now? Shaperon reported just US$190.3K in revenue for 2025, against an accumulated deficit of US$110.9M. As a drug developer, it spends years on trials before products earn anything; its lead program, Nugel for atopic dermatitis, has completed a Phase 2b trial.
What's the endgame? The purchase ties to a KOSDAQ listing test. Korea's second market flags a listed company when its pre-tax loss grows large relative to equity, and Shaperon must hold that ratio under 50% in 2026. A subsidiary with US$14.3M in revenue changes the math directly.
The financing: Shaperon arranged the money in advance, deciding in April 2026 to issue US$7.21M of convertible bonds, with US$3.61M earmarked for acquisitions. The final price came in US$503K under that budget.
The signal: Rather than funding drug development with equity, Shaperon bought a cash engine. It is an unusual move in a global skincare market where strategic buyers are consolidating premium assets — GaldermaDealroom has a profile for this one. Try Dealroom →'s planned $1.5 billion purchase of ZO Skin HealthDealroom has a profile for this one. Try Dealroom → and PAI PartnersDealroom has a profile for this one. Try Dealroom →' deal for ElemisDealroom has a profile for this one. Try Dealroom → show where capital is flowing. Shaperon's bet is smaller and defensive: revenue to keep its listing intact.
Read more: parallel37.kr
Image credit: "Bristol-Myers-Squibb Pharmaceutical Research Institute" by Sue Adair, licensed under CC BY-SA 2.0